A Study of the Safety of R256918 in Obese Patients
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
This study investigates the safety of 12 weeks of treatment with R256918, in obese patients
(JNJ-16269110 and R256918 are different names for the same molecule). The primary objective
of the study is to investigate mean changes in Hepatic Triglyceride Content (HTGC), which is
the fat content of the liver, from baseline to week 6 and 12 by 1H-Magnetic Resonance
Spectroscopy (MRS), a specialized non invasive radiology test. Additional measures include
body mass index (BMI), fasting glucose,lipid levels, and blood pressure. Safety assessments
performed during the trial include laboratory tests, vital sign measurements, and adverse
event reporting.
Phase:
Phase 2
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.